Journal List > Endocrinol Metab > v.25(3) > 1085829

TOOLS
Nam, Shin, Oh, Rhie, Yoo, Park, and Lee: The Comparison of Clinical Factors according to Growth Velocity during Gonadotropin-Releasing Hormone Agonist Treatment in Central Precocious Puberty Girls
Original Article
Endocrinology and Metabolism

Endocrinology and Metabolism 2010; 25(3): 206-212.

Published online: 30 September 2010

DOI: https://doi.org/10.3803/EnM.2010.25.3.206

The Comparison of Clinical Factors according to Growth Velocity during Gonadotropin-Releasing Hormone Agonist Treatment in Central Precocious Puberty Girls

Hyo Kyoung Nam, Jung Yeon Shin, Yeon Joung Oh1, Young Jun Rhie, Young Yoo, Sang Hee Park, Kee-Hyoung Lee

Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.

1Department of Pediatrics, Sahm Yook Medical Center, Seoul, Korea.

Corresponding author: Kee-Hyoung Lee. Department of Pediatrics, Korea University College of Medicine, Anam-dong 5ga, Sungbuk-gu, Seoul 136-705, Korea. Tel: +82-2-920-5090, Fax: +82-2-922-7476, khlee218@kumc.or.kr

Received 27 October 2009       Accepted 29 May 2010

Copyright © 2010 Korean Endocrine Society

Abstract

Background

The aim of this study was to investigate the favorable factors for gonadotropin-releasing hormone (GnRH) agonist treatment with regard to the growth velocity and the predicted adult height (PAH) in central precocious puberty (CPP) girls.

Methods

We reviewed the clinical and auxological parameters in 46 CPP girls who were treated with GnRH agonist at the pediatric endocrinology clinic of Korea University Hospital from January 2001 to August 2007. We divided the two groups according to the growth velocity of 5 cm/yr and we assessed the related factors associated with growth velocity. We also assessed the changes in PAH for two years.

Results

The pretreatment chronological age and bone age were significantly younger in the high growth velocity group (> 5 cm/yr) compared to that of the low growth velocity group (7.8 ± 0.9 year vs. 8.4 ± 0.5 year, 9.4 ± 1.2 year vs. 10.1 ± 0.9 year, respectively) (P < 0.05). The PAH after treatment was significantly greater in the high growth velocity group (> 5 cm/yr)(P < 0.05). Growth velocity during treatment had negative correlation with the pretreatment chronological age and positive correlation with the PAH after one and two years of treatment (r = -0.45, P < 0.05 and r = 0.51, P < 0.01). PAH had positive correlation with the treatment duration (r = 0.31, P < 0.05).

Conclusion

In our study, the growth velocity during GnRH agonist treatment was negatively related to age at the initiation of treatment. Therefore, earlier treatment is important to improve the outcomes and to maintain appropriate growth velocity in CPP girls.

Keywords: Gonadotropin releasing hormone agonist, Growth velocity, Precocious puberty, Predicted adult height

Figures and Tables

Fig. 1
Relationship between growth velocity and chronological age before treatment.
enm-25-206-g001
Fig. 2
Relationship between growth velocity and predicted adult height after two year treatment.
enm-25-206-g002
Fig. 3
Comparisons of between target adult height and predicted adult height during two year treatment.
PAH, predicted adult height; TAH, target adult height.
enm-25-206-g003
Table 1
Clinical and auxological characteristics of subjects before GnRH agonist treatment
enm-25-206-i001

Data are presented as mean ± SD.

BA, bone age; BMI, body mass index; CA, chronological age; PAH, predicted adult height; SDS, standard deviation score; TAH, target adult height.

Table 2
Clinical and auxological characteristics of subjects according to growth velocity: before treatment
enm-25-206-i002

Data are presented as mean ± SD.

BA, bone age; BMI, body mass index; CA, chronological age; FSH, follicular stimulating hormone; LH, luteinizing hormone; PAH, predicted adult height; SDS, standard deviation score; TAH, target adult height.

Table 3
Clinical and auxological data according to growth velocity: after treatment
enm-25-206-i003

ΔHeight SDS, height after treatment-height before treatment.

ΔPAH SDS, PAH after treatment-PAH before treatment.

ΔBA-CA, bone age advancement after treatment-bone age advancement before treatment.

Data are presented as mean ± SD.

BA, bone age; CA, chronological age; PAH, predicted adult height; SDS, standard deviation score.

Table 4
Correlation coefficients of growth velocity with other parameter
enm-25-206-i004

BA, bone age; CA, chronological age; PAH, predicted adult height; TAH, target adult height.

Table 5
Correlation coefficients of predicted adult height with other parameter
enm-25-206-i005

CA, chronological age.

References

1. Papadimitriou A, Beri D, Tsialla A, Fretzayas A, Psychou F, Nicolaidou P. Early growth acceleration in girls with idiopathic precocious puberty. J Pediatr. 2006. 149:43–46.
2. Yoo SY, Yoo HW. Effects of treatment with long-acting gonadotropin-releasing hormone agonist on somatic growth in patients with central precocious puberty. J Korean Soc Pediatr Endocrinol. 1998. 3:59–67.
3. Traggiai C, Stanhope R. Disorders of pubertal development. Best Pract Res Clin Obstet Gynaecol. 2003. 17:41–56.
4. Kakarla N, Bradshaw KD. Disorders of pubertal development: precocious puberty. Semin Reprod Med. 2003. 21:339–351.
5. Mrug S, Elliott M, Gilliland MJ, Grunbaum JA, Tortolero SR, Cuccaro P, Schuster M. Positive parenting and early puberty in girls: protective effects against aggressive behavior. Arch Pediatr Adolesc Med. 2008. 162:781–786.
6. Mul D, de Muinck Keizer-Schrama SM, Oostdijk W, Drop SL. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty. Horm Res. 1999. 51:270–276.
7. Mansfield MJ, Beardsworth DE, Loughlin JS, Crawford JD, Bode HH, Rivier J, Vale W, Kushner DC, Crigler JF Jr, Crowley WF Jr. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. N Engl J Med. 1983. 309:1286–1290.
8. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update. 2004. 10:135–147.
9. Sperling M. Pediatric endocrinology. 2008. 3rd ed. Philadelphia: WB Saunders Co;2565–2073.
10. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 1959. 2nd ed. California: Stanford University Press.
11. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952. 40:423–441.
12. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969. 44:291–303.
13. Garibaldi L. Kliegman R, Nelson WE, editors. Disorders of pubertal development. Nelson textbook of pediatrics. 2007. 18th ed. Philadelphia: Saunders Co;2309–2311.
14. Phillip M, Lazar L. Precocious puberty: growth and genetics. Horm Res. 2005. 64:56–61.
15. Paik KH, Jin DK. Etiology and age incidence of precocious puberty. J Korean Soc Pediatr Endocrinol. 2002. 7:199–205.
16. Shin CH, Hwang JS, Lim JS, Kim SY, Shim KS, Yang SW, Yu JS. Growth and growth-determining factors in girls with idiopathic central precocious puberty treated with long-acting luteinizing hormone-releasing hormone analogue. J Korean Soc Pediatr Endocrinol. 1997. 2:217–225.
17. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab. 1991. 73:1235–1240.
18. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004. 6:211–231.
19. Choi JH. Proper dosage and duration of GnRH agonist treatment in central precocious puberty. J Korean Soc Pediatr Endocrinol. 2006. 11:8–14.
20. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol. 2008. 159:S3–S8.
21. Weise M, Flor A, Barnes KM, Cutler GB Jr, Baron J. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. J Clin Endocrinol Metab. 2004. 89:103–107.
22. Moon JS, Lee SY, Nam CM, Choi JM, Choe BK, Seo JW, Oh K, Jang MJ, Hwang SS, Yoo MH, Kim YT, Lee CG. 2007 Korean National Growth Charts: review of developmental process and an outlook. Korean J Pediatr. 2008. 51:1–25.
23. Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF Jr, Crawford JD, Crowley WF Jr. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev. 1986. 7:24–33.
24. Perry RJ, Farquharson C, Ahmed SF. The role of sex steroids in controlling pubertal growth. Clin Endocrinol (Oxf). 2008. 68:4–15.
25. Attie KM, Ramirez NR, Conte FA, Kaplan SL, Grumbach MM. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids. J Clin Endocrinol Metab. 1990. 71:975–983.
26. Rodd C, Jourdain N, Alini M. Action of estradiol on epiphyseal growth plate chondrocytes. Calcif Tissue Int. 2004. 75:214–224.
27. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, Borrelli P, Crisafulli G, Wasniewska M, De Luca F. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 1999. 141:140–144.
28. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001. 86:4711–4716.
29. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007. 92:3483–3489.
30. Oostdijk W, Drop SL, Odink RJ, Hummelink R, Partsch CJ, Sippell WG. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group. Acta Paediatr Scand Suppl. 1991. 372:39–45.
TOOLS
Similar articles